MK 5172, also known as Grazoprevir, is a second-generation NS3/4A protease inhibitor that is often used in combination with the second-generation NS5A inhibitor, Elbasvir (E501010), for the treatment of hepatitis C virus infection. It is a COVID19-related research product.
